Lester Jenkins v. BP Exploration & Production Inc.

CourtCourt of Appeals for the Eleventh Circuit
DecidedOctober 18, 2024
Docket23-11538
StatusPublished

This text of Lester Jenkins v. BP Exploration & Production Inc. (Lester Jenkins v. BP Exploration & Production Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lester Jenkins v. BP Exploration & Production Inc., (11th Cir. 2024).

Opinion

USCA11 Case: 23-11535 Document: 77-1 Date Filed: 10/18/2024 Page: 1 of 21

[PUBLISH] In the United States Court of Appeals For the Eleventh Circuit

____________________

No. 23-11535 ____________________

In Re: DEEPWATER HORIZON BELO CASES, _______________________________________________ BELO PLAINTIFFS, Plaintiffs, LESTER JENKINS, DWIGHT SIPLES, Interested Parties-Appellants, versus BP EXPLORATION & PRODUCTION, INC., BP AMERICA PRODUCTION COMPANY,

Defendants-Appellees. USCA11 Case: 23-11535 Document: 77-1 Date Filed: 10/18/2024 Page: 2 of 21

2 Opinion of the Court 23-11535

Appeal from the United States District Court for the Northern District of Florida D.C. Docket No. 3:19-cv-00963-MCR-HTC ____________________

No. 23-11538 ____________________

LESTER EUGENE JENKINS, Plaintiff-Appellant, DWIGHT SIPLES, Interested Party-Appellant, versus BP EXPLORATION & PRODUCTION INC, BP AMERICA PRODUCTION COMPANY,

Defendants-Appellees.

Appeal from the United States District Court for the Northern District of Florida USCA11 Case: 23-11535 Document: 77-1 Date Filed: 10/18/2024 Page: 3 of 21

23-11535 Opinion of the Court 3

D.C. Docket No. 5:19-cv-00260-MCR-HTC ____________________

No. 23-11539 ____________________

DWIGHT SIPLES, JR., Plaintiff-Appellant, LESTER JENKINS, Interested Party-Appellant, versus BP EXPLORATION & PRODUCTION, INC., BP AMERICA PRODUCTION COMPANY,

Appeal from the United States District Court for the Northern District of Florida D.C. Docket No. 5:19-cv-00310-MCR-HTC ____________________ USCA11 Case: 23-11535 Document: 77-1 Date Filed: 10/18/2024 Page: 4 of 21

4 Opinion of the Court 23-11535

Before WILLIAM PRYOR, Chief Judge, and LUCK and ED CARNES, Cir- cuit Judges. WILLIAM PRYOR, Chief Judge: This appeal asks whether the district court abused its discre- tion when it excluded expert opinion testimony about general cau- sation in a suit related to the Deepwater Horizon oil spill. Lester Jen- kins and Dwight Siples Jr. participated in the cleanup of that spill. And both men complain that their exposure to crude oil and dis- persants during the cleanup caused chronic sinusitis. Because nei- ther crude oil nor dispersants are known toxins, Jenkins and Siples needed to prove general causation. Their expert witnesses opined that a causal relationship existed between the cleanup work and chronic sinusitis. But the district court ruled that neither expert identified a minimal level of exposure at which crude oil, its disper- sants, or the chemicals associated with either are hazardous to hu- man beings. And it found that the experts failed to identify a statis- tically significant association between the chronic conditions and exposure to crude oil, assess various studies’ limitations, or mean- ingfully consider causal factors. Because the district court did not abuse its discretion, we affirm the summary judgment against Jen- kins and Siples. I. BACKGROUND This appeal rises and falls on the admission of expert evi- dence and the scientific methodologies that ground toxic-tort ac- tions. So we begin with a short primer on those methods and the USCA11 Case: 23-11535 Document: 77-1 Date Filed: 10/18/2024 Page: 5 of 21

23-11535 Opinion of the Court 5

burdens of proof relevant to these suits. Then we turn to the facts and procedural history for this appeal. A. A Primer on Toxic Torts Toxic-tort actions come in two forms. In the first, the medi- cal community already recognizes that a specific “agent”—i.e., a substance external to the human body (think drugs, chemicals, minerals)—is toxic and capable of “caus[ing] the type of harm a plaintiff alleges.” McClain v. Metabolife Int’l, Inc., 401 F.3d 1233, 1239 (11th Cir. 2005). In these actions, the parties battle over specific causation only: that is, whether the agent caused a specific plain- tiff’s disease. Id. In the second, the medical community does not recognize an agent as both toxic and capable of causing the kind of injury a plaintiff alleges. Id. Plaintiffs in these actions must establish both general and specific causation. General causation asks “whether an agent increases the inci- dence of disease in a group and not whether the agent caused any given individual’s disease.’’ Michael D. Green et al., Reference Guide on Epidemiology, in REFERENCE MANUAL ON SCIENTIFIC EVIDENCE 549, 623 (Fed. Jud. Ctr., 3d ed. 2011). In toxic-tort actions, plaintiffs prove general causation through epidemiological evidence, dose- response relationship, and background risk of disease. Chapman v. Procter & Gamble Distrib., LLC, 766 F.3d 1296, 1308 (11th Cir. 2014). Because these three kinds of evidence underpin our general-causa- tion precedent, we describe each briefly. Epidemiology. Epidemiology “studies the incidence, distribu- tion, and [cause] of disease in human populations.” Green, supra, at USCA11 Case: 23-11535 Document: 77-1 Date Filed: 10/18/2024 Page: 6 of 21

6 Opinion of the Court 23-11535

551. Experts who rely on epidemiological evidence to establish general causation assess that evidence in two steps. To start, they ask whether the evidence “reveal[s] an association between an agent and [a] disease.” Id. at 554. To identify an association, experts must rule out alternative explanations, by asking, for example, whether a potential association resulted from limitations in the study, like chance or bias. Id. at 554, 572. Experts also ask “whether the association reflects a true cause-effect relationship.” Id. at 554, 597. In this context, causation means something akin to but-for cause: exposure to a toxic agent is “a necessary link in [the] chain of events” that led to the disease. Id. at 597–98. To decide whether a particular study supports a causal infer- ence, experts consider the nine factors developed by Sir Austin Bradford Hill: (1) temporal relationship; (2) strength of the associa- tion; (3) dose-response relationship; (4) replication of the findings; (5) biological plausibility; (6) consideration of alternative explana- tions; (7) cessation of exposure; (8) specificity of the association; and (9) consistency with other knowledge. Id. at 600 (citing Austin Bradford Hill, The Environment and Disease: Association or Causation?, 58 Proc. Royal Soc’y Med. 295, 295–300 (1965)). No factor is dispos- itive. And “[n]o algorithm exists for applying the Hill guidelines.” Restatement (Third) of Torts: Liability for Physical and Emotional Harm § 28 cmt. c(3) (Am. L. Inst. 2010). Instead, their application requires judgment. Id. Dose-Response Relationship. At a high level, “a dose-response relationship means the greater the exposure, the greater the risk of USCA11 Case: 23-11535 Document: 77-1 Date Filed: 10/18/2024 Page: 7 of 21

23-11535 Opinion of the Court 7

disease.” Green, supra, at 603. At a more granular level, the term describes “a relationship in which a change in amount, intensity, or duration of exposure to [a chemical] is associated with a change— either an increase or decrease—in risk.” McClain, 401 F.3d at 1241– 42 (citation and internal quotation marks omitted). This relation- ship is “the hallmark of basic toxicology” because “all substances potentially can be toxic.” Chapman, 766 F.3d at 1307. Most “low dose exposures—even for many years—will have no conse- quence[s] at all.” McClain, 401 F.3d at 1242 (citation and internal quotation marks omitted). This fact makes “[d]ose . . . the single most important factor to consider in evaluating whether an alleged exposure caused a specific adverse effect.” Id. (citation and internal quotation marks omitted). Background Risk of Disease.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Richard Junior Frazier
387 F.3d 1244 (Eleventh Circuit, 2004)
Rink v. Cheminova, Inc.
400 F.3d 1286 (Eleventh Circuit, 2005)
Johnny C. McClain v. Metabolife International, Inc
401 F.3d 1233 (Eleventh Circuit, 2005)
United States v. Ronald Keith Brown
415 F.3d 1257 (Eleventh Circuit, 2005)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
United States v. Irey
612 F.3d 1160 (Eleventh Circuit, 2010)
Douglas C. Kilpatrick v. Breg, Inc.
613 F.3d 1329 (Eleventh Circuit, 2010)
Mitchell v. Gencorp Inc.
165 F.3d 778 (Tenth Circuit, 1999)
Wright v. Willamette Industries, Inc.
91 F.3d 1105 (Eighth Circuit, 1996)
Seamon Ex Rel. Estate of Seamon v. Remington Arms Co.
813 F.3d 983 (Eleventh Circuit, 2016)
Teresa Taylor v. Mentor Worldwide, LLC
940 F.3d 582 (Eleventh Circuit, 2019)
United States v. David Ming Pon
963 F.3d 1207 (Eleventh Circuit, 2020)
Westberry v. Gislaved Gummi AB
178 F.3d 257 (Fourth Circuit, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
Lester Jenkins v. BP Exploration & Production Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/lester-jenkins-v-bp-exploration-production-inc-ca11-2024.